ReviewTherapeutic advances in hematology2017

The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.

Jason Brayer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.